Burden of hepatocellular carcinoma in Asia

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 12, 2012, Pages 5955-5958

  Fazeli, Zeinab ^a   Pourhoseingholi, Mohamad Amin ^a   Vahedi, Mohsen ^b   Zali, Mohammad Reza ^a  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Asia; Burden; Hepatocellular carcinoma

Indexed keywords

EID: 84877098484     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.12.5955     Document Type: Review

References (59)

1. Alavian SM, Fallahian F, Lankarani KB (2007). The changing epidemiology of viral hepatitis B in Iran. J Gastrointestin Liver Dis, 16, 403-6.
2. Anand R (2002). Aflatoxins, in: IARC monograph on the evaluation of carcinogenic risks to humans, vol. 82, in: Some Traditional Herbal Medicines Some Mycotoxins, Naphthalene and Styrene, McGraw-Hill, New York, 171-300.
3. Bae JM, Jung KW, Won YJ (2002). Estimation of cancer deaths in Korea for the upcoming years. J Korean Med Sci, 17, 611-5.
4. Blumberg BS (2010). Primary and secondary prevention of liver cancer caused by HBV. Front Biosci (Schol Ed), 1, 756-63.
5. Cai L, Chongsuvivatwong V, Geater A (2008). Changing pattern of premature mortality burden over 6 years of rapid growth of the economy in suburban south-west China: 1998-2003. Public Health, 122, 478-86.
6. CDC (2003). Global progress toward universal childhood hepatitis B vaccination, 2003. MMWR, 52, 868-9.
7. Chang MH, Chen CJ, Lai MS, et al (1997). Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. N Engl J Med, 336, 1855-9.
8. Chen JG, Zhang SW (2011). Liver cancer epidemic in China: past, present and future. Semin Cancer Biol, 21, 59-69.
9. Colombo M, Kuo G, Choo Q, et al (1989). Prevalence of antibodies to hepatitis C virus in Italian patients with Hepatocellular carcinoma. Lancet, 2, 1006-8.
10. Chen DS (1993). From hepatitis to hepatoma: lessons from type B viral hepatitis. Science, 262, 369-70.
11. Chen DS (1995). Hepatitis C virus in chronic liver disease and hepatocellular carcinoma in Taiwan. Princess Takamatsu Symp, 25, 27-32.
12. Chen CH, Chen YY, Chen GH, et al (2004). Hepatitis B virus and hepatocarcinogenesis: a 9 year retrospective cohort of 13676 relatives with hepatocellular carcinoma. J Hepatol, 40, 653-9
13. Chen CJ, Yu MW, Liaw YF (1997). Epidemiological characteristics and risk factors of hepatocellular carcinoma. J Gastroenterol Hepatol, 12, 294-308.
14. Chuang SC, La Vecchia C, Boffetta P (2009). Liver cancer: descriptive epidemiology and risk factors other than HBV and HCV infection. Cancer Lett, 286, 9-14.
15. Deuffic S, Poynard T, Buffa L, Valleron AJ (1998). Trends in primary liver cancer. Lancet, 351, 214-5.
16. Di Bisceglie AM, Lyra AC, Schwartz M, et al (2003). Hepatitis C-related hepatocellular carcinoma in the United States: influence of ethnic status. Am J Gastroenterol, 98, 2060-3.
17. Drinking in the United States: main findings from the 1992 National Longitudinal Alcohol Epidemiology Survey (NLAES) (1998). US Alcohol epidemiology Data Reference Manual, Volume 6, First Edition. NIAAA/NIH NIH Publication No. 99-3519.
18. Fallot G, Neuveut C, Buendia MA (2012). Diverse roles of hepatitis B virus in liver cancer. Curr Opin Virol, 2, 467-73.
19. Gomaa AI, Khan SA, Toledano MB, et al (2008). Hepatocellular carcinoma: Epidemiology, risk factors and pathogenesis. World J Gastroenterol, 14, 4300-8.
20. Gwack J, Park SK, Lee EH, et al (2011). Hepatitis B vaccination and liver cancer mortality reduction in Korean children and adolescents. Asian Pac J Cancer Prev, 12, 2205-8.
21. Hajiani E, Masjedzadeh R, Hasehemi J, et al (2005). Risk factors for hepatocellulr carcinoma in southern Iran. Saudi Med J, 26, 974-7.
22. Han KH, Ahn SH (2005). How to predict HCC development in patents with chronic B-viral liver disease? Intervirology, 48, 23-8.
23. Huang JQ, Zheng GF, Lai CL, et al (2011). Risk of liver cancer in patients with hepatitis B or C. Hong Kong Med J, 17, 41-3.
24. IARC (1987). Monographs, Overall Evaluations of Carcinogenicity: An Updating of IARC Monographs, vol. 1-42, supplement 7. Lyon: IARC Press.
25. Kao JH, Chen DS (2005). Changing disease burden of hepatocellular carcinoma in the Far East and Southeast Asia. Liver Int, 25, 696-703.
26. Kao JH, Tsai SL, Chen PJ, et al (1994). A clinicopathologic study of chronic non-A, non-B (type C) hepatitis in Taiwan: comparison between posttransfusion and sporadic patients. J Hepatol, 21, 244-9.
27. Kao JH, Chen DS (1999). Hepatocellular carcinoma in Taiwan: progress in the past decade 1988-1997. In: Leong ASY, Liew CT, Lau JWY, Johnson PJ, eds. Hepatocellular Carcinoma: Contemporary Diagnosis, Investigation and Management. London: Arnold, 235-50.
28. Kim SR, Kudo M, Hino O, et al (2008). Epidemiology of hepatocellular carcinoma in Japan and Korea. A review. Oncology, 75, 13-6.
29. Kumar V, Fausto N, Abbas A (editors) (2003). Robbins & Cotran Pathologic Basis of Disease (7th ed.). Saunders. pp. 914-7.
30. Koriech O, Al-Kuhaymi R (1994). Profile of cancer in Riyadh armed forces hospital. Ann Saudi Med, 14, 187-94.
31. Lai EC, Lau WY (2005). The continuing challenge of hepatic cancer in Asia. Surgeon, 3, 210-5.
32. Law MG, Roberts SK, Dore GJ, Kaldor JM (2000). Primary hepatocellular carcinoma in Australia, 1978-1997: Increasing incidence and mortality. Med J Aust, 173, 403-5.
33. Liu Y, Chang CC, Marsh GM, Wu F (2012). Population attributable risk of aflatoxin-related liver cancer: systematic review and meta-analysis. Eur J Cancer, 48, 2125-36.
34. Liu Y, Wu F (2010). Global burden of aflatoxin-induced hepatocellular carcinoma: a risk assessment. Environ Health Perspect, 118, 818-24.
35. Makimoto K, Higuchi S (1999). Alcohol consumption as a major risk factor for the rise in liver cancer mortality rates in Japanese men. Int J Epidemiol, 28, 30-4.
36. Matsuda T, Saika K (2012). Trends in liver cancer mortality rates in Japan, USA, UK, France and Korea based on the WHO mortality database. Jpn J Clin Oncol, 42, 360-1.
37. McGlynn KA, London WT (2005). Epidemiology and natural history of hepatocellular carcinoma. Best Pract Res Clin Gastroenterol, 19, 3-23.
38. McGlynn KA, Tsao L, Hsing AW, et al (2001). International trends and patterns of primary liver cancer. Int J Cancer, 94, 290-6.
39. Merat S, Malekzadeh R, Rezvan H, Khatibian M (2000). Hepatitis B in Iran. Arch Iran Med, 3, 192-201.
40. Ming L, Thorgeirsson SS, Gail MH, et al (2002). Dominant role of hepatitis B virus and cofactor role of aflatoxin in hepatocarcinogenesis in Qidong, China. Hepatology, 36, 1214-20.
41. Noh DK, Choi KS, Jun JK, et al (2012). Factors associated with attending the national cancer screening program for liver cancer in Korea. Asian Pac J Cancer Prev, 13, 731-6.
42. Okuda K (1992). Hepatocellular carcinoma: Recent progress. Hepatology, 5, 948-63.
43. Oshima A, Tsukuma H, Hiyama T, et al (1984). Follow-up study of HBsAg-positive blood donors with special reference to effect of drinking and smoking on development of liver cancer. Int J Cancer, 34, 775-9.
44. Park JW, Kim CM (2005). Epidemiology of heptocellular carcinoma in Korea. Korean J Hepatol, 11, 303-10.
45. Parkin DM, Bray F, Ferlay J, Pisani P (2005). Global cancer statistics, 2002. CA Cancer J Clin, 55, 74-108.
46. Parkin DM, Whelan SL, Ferlay J, et al (2002). Cancer Incidence in Five Continents IARC Scientific Publications No. 155, vol. VIII. Lyon: IARC Press.
47. Pourhoseingholi MA, Fazeli Z, Zali MR, Alavian SM (2010). Burden of hepatocellular carcinoma in Iran; Bayesian projection and trend analysis. Asian Pac J Cancer Prev, 11, 859-62.
48. Qian GS, Ross RK, Yu MC, et al (1994). A follow-up study of urinary markers of aflatoxin exposure and liver cancer risk in Shanghai, people's republic of China. Cancer Epidemiol Biomarkers Prev, 3, 3-10.
49. Siddique I, El-Naga HA, Memon A, et al (2004).CLIP score as a prognostic indicator for Hepatocellular carcinoma: experience with patients in the Middle East. Euro J Gastro Hepatol, 16, 675-80.
50. Sin HR, Lee CU, Park HJ, et al (1996). Hepatitis B and C virus, for the risk of liver cancer: a case-control study in Pusan, Korea. Int J Epidemiol, 25, 933-40.
51. Shamszad M, Farzadgan H (1982). Hepatitis B related cirrhosis and hepatocellular carcinoma in Iran. J Iranian Med Council, 8, 238.
52. Sun CA, Wu DM, Lin CC, et al (2003). Incidence and cofactors of hepatitis C virus-related hepatocellular carcinoma: a prospective study of 12,008 men in Taiwan. Am J Epidemiol, 157, 674-82.
53. Taylor-Robinson SD, Foster GR, Arora S, et al (1997). Increase in primary liver cancer in the UK, 1979-1994. Lancet, 350, 1142-3.
54. Teo EK, Fock KM (2001). Hepatocellular Carcinoma: An Asian Perspective. Dig Dis, 19, 263-8.
55. Yang GH, Wang JF, Wan X, et al (2005). Quantitative analysis of factors affected mortality trend in Chinese, 2002. Zhonghua Liu Xing Bing Xue Za Zhi, 26, 934-8.
56. Yoshimi I, Sobue T (2003). Mortality trend of liver cancer in Japan: 1960-2000. Jpn J Clin Oncol, 33, 202-3.
57. You SL ,Yang HI, Chen CJ (2004). Seropositivity of hepatitis B e antigen and hepatocellular carcinoma. Ann Med, 36, 215-24.
58. Yu MC, Yuan, J-M, Govindarajan S, Ross RK (2000). Epidemiology of hepatocellular carcinoma. Can J Gastroenterol, 14, 703-9.
59. World Health Organization (2007). Cancer. http://www.who.int/mediacentre/factsheets/fs297/en/